#1 Probiotic for healthcare professionals
New research has shown that Symprove is the probiotic most recommended by gastroenterologists, dietitians and GPs.1* Why? Because it's proven in randomised controlled trials at leading institutions, and 92% of people report a difference in real-world.2-5
Why water is life for our bacteria
Symprove multi-strain bacteria are suspended in a unique water-based solution to ensure they're metabolically active and quickly pass through the stomach with limited exposure to gastric juices.6
- ARRIVE: 10 billion live colony forming units (CFUs) per dose6
- SURVIVE: Pass through the stomach in <10 minutes6
- THRIVE: >99% of live bacteria consumed reach the colon6
Proud partners
Trial Symprove
50,000 people have already started Symprove based on the recommendation of their healthcare professional.1*
Book a 20-min virtual session to hear the evidence behind Symprove, receive a free trial and get exclusive discounts for your patients.‡
Can't find a suitable time or prefer a 1-2-1 session? Book a personal meeting.
Recommended by clinical and scientific experts
We are proud to partner with Symprove to raise awareness of a product that has already been helpful to so many people
Symprove is different from other probiotics because it is water-based, which means it limits exposure to gastric juices and digestive enzymes
In a world where there are many claims about gut health (with good evidence!), I’m so enthused by Symprove's research, and what we are seeing from the results.
In order to be effective, probiotics need to 'arrive, survive and thrive'
92% of people report a difference with Symprove over 3 months and we offer healthcare professionals a free trial to see for themselves
Symprove has been proven in a number of rigorous randomised double-blind controlled trials... supported by several studies in-vitro, demonstrating changes in physiological and microbiological effects
Educational resources
CPD
Expert articles
Webinars
Here's the latest...
- Data on file, 2024.
- Sisson G, et al. Aliment Pharmacol Ther 2014;40(1):51–62.
- Kvasnovsky CL, et al. Inflammopharmcology 2017; doi: 10.1007/s10787-017-0363-y.
- Bjarnason I, et al. Inflammopharmacology 2019;27(3):465–473.
- Rudland S, et al. Journal of Primary Care and General Practice 2021:4(4).
- Fredua-Agyeman M, et al. Benef Microbes 2015;6(1):141–51.
*Based on external survey (n=432 healthcare professionals), conducted and independently analysed by specialist research agency, 2024.
†New customers who have purchased Symprove based on a healthcare professional recommendation since January 2020.
‡Offer valid for healthcare professionals who have not previously received a free Symprove trial.
